Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 100.97 M
The data is delayed by 15 minutes.
ASMB is in the long-term down -80% below S&P in 3 years.
Description: Assembly Biosciences, Inc. provides development and commercialization of gastrointestinal products in the United States. The company is developing two late-stage development product candidates, including VEN 307, a diltiazem cream for the relief of pain associated with anal fissures; and VEN 308, a phenylephrine gel for the treatment of fecal incontinence associated with ileal pouch anal anastomosis. It is also involved in the development of VEN 310 as a colonic delivery mechanism, which is a PH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules, and other treatments. The company was formerly known as Ventrus Biosciences Inc. and changed its name to Assembly Biosciences, Inc. in July, 2014. Assembly Biosciences, Inc. was founded in 2005 and is based in New York, New York.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||17.23 M||EPS||-2.74||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-7.94|
|P/E To EPS Growth||P/S||P/BV||0.81||Price/Cash Per Share|
|Price/Free Cash Flow||-6.68||ROA||-19.42%||ROE||-21.56%||ROI|
|Current Ratio||45.27||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.02|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||70.67 M||Cash From Investing Activities||-30 K||Cash From Operating Activities||-3.67 M||Gross Profit|
|Net Profit||-7.14 M||Operating Profit||-7.2 M||Total Assets||138.35 M||Total Current Assets||96.34 M|
|Total Current Liabilities||2.13 M||Total Debt||Total Liabilities||13.73 M||Total Revenue|
|High 52 week||31.94||Low 52 week||8.36||Last close||9.3||Last change||3.22%|
|RSI||24.52||Average true range||0.82||Beta||0.87||Volume||30.34 K|
|Simple moving average 20 days||-12.93%||Simple moving average 50 days||-19.04%||Simple moving average 200 days||-42.12%|
|Performance Week||3.56%||Performance Month||-22.5%||Performance Quart||-33.67%||Performance Half||-42.8%|
|Performance Year||-61.27%||Performance Year-to-date||-58.89%||Volatility daily||5.64%||Volatility weekly||12.6%|
|Volatility monthly||25.83%||Volatility yearly||89.47%||Relative Volume||234.77%||Average Volume||271.26 K|
|New High||New Low|
2020-05-27 08:00:10 | Assembly Biosciences Announces Management Transition
2020-05-26 08:00:10 | Assembly Biosciences to Present During the Jefferies Virtual Healthcare Conference
2020-05-15 11:14:03 | Why Assembly Biosciences ASMB Stock Might be a Great Pick
2020-05-13 10:58:02 | Will Assembly Biosciences Continue to Surge Higher?
2020-05-06 06:33:01 | Should Assembly Biosciences NASDAQ:ASMB Be Disappointed With Their 33% Profit?
2020-05-01 17:00:10 | Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635c4
2020-03-31 16:05:10 | Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635c4
2020-03-30 08:00:10 | Assembly Biosciences Appoints Jason Okazaki as Chief Legal and Business Officer
2020-03-04 18:05:11 | Assembly Biosciences ASMB Reports Q4 Loss, Tops Revenue Estimates
2020-03-04 16:05:10 | Assembly Biosciences Reports Fourth Quarter and Year End 2019 Financial Results
2020-02-20 12:31:05 | Will Assembly Biosciences ASMB Report Negative Q4 Earnings? What You Should Know
2020-01-28 06:00:53 | Does The Assembly Biosciences, Inc. NASDAQ:ASMB Share Price Tend To Follow The Market?
2019-12-12 06:30:10 | Assembly Biosciences Announces Pricing of $125 Million Public Offering
2019-12-11 16:03:10 | Assembly Biosciences Announces Proposed Public Offering of Common Stock
2019-12-11 12:17:49 | Did Hedge Funds Drop The Ball On Assembly Biosciences Inc ASMB ?
2019-12-10 11:11:00 | Stock Upgrades: Assembly Biosciences Shows Rising Relative Strength
2019-12-06 08:00:10 | Assembly Biosciences Announces Plenary Lecture at HEP DART 2019
2019-11-18 08:00:00 | Assembly Biosciences Announces Presentation at Jefferies London Healthcare Conference
2019-11-11 08:00:00 | Data for Assembly Biosciences’ First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019
2019-11-08 16:13:07 | Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock
2019-11-07 17:30:00 | Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635c4
2019-11-07 16:05:00 | Assembly Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights
2019-11-07 08:00:00 | Assembly Biosciences Appoints Luisa Stamm, MD, PhD, as Chief Medical Officer
2019-11-06 16:40:22 | Hedge Funds Are Selling Assembly Biosciences Inc ASMB
2019-10-31 10:47:02 | Can Segmental Growth Aid Hologic HOLX in Q4 Earnings?
2019-10-30 06:58:23 | Estimating The Fair Value Of Assembly Biosciences, Inc. NASDAQ:ASMB
2019-10-28 17:15:05 | Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635c4
2019-10-28 08:00:05 | Assembly Biosciences Appoints Thomas J. Russo as Chief Financial Officer
2019-10-18 11:02:03 | What's in Store for Thermo Fisher TMO in Q3 Earnings?
2019-10-18 10:09:02 | Top Ranked Momentum Stocks to Buy for October 18th
2019-10-17 16:27:09 | This Biotech Stock Nearly Doubled In Two Days On A Potential Hepatitis Cure
2019-10-16 07:05:00 | Safety and Antiviral Activity of Assembly Biosciences’ First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASLD
2019-09-23 08:14:12 | Will Assembly Biosciences Continue to Surge Higher?
2019-09-15 09:16:24 | Investors Who Bought Assembly Biosciences NASDAQ:ASMB Shares A Year Ago Are Now Down 67%
2019-08-09 16:30:00 | Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635c4
2019-08-05 19:25:11 | Assembly Biosciences ASMB Reports Q2 Loss, Lags Revenue Estimates
2019-08-05 16:05:00 | Assembly Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights
2019-07-17 13:08:50 | Does The Assembly Biosciences, Inc. NASDAQ:ASMB Share Price Tend To Follow The Market?